Skip to main content
Circio Holding ASA logo

Circio Holding ASA — Investor Relations & Filings

Ticker · CRNA ISIN · NO0013033795 LEI · 5967007LIEEXZXFYNS31 OL Professional, scientific and technical activities
Open in API
Filings indexed 167 across all filing types
Latest filing 2026-04-08 Share Issue/Capital Cha…
Country NO Norway
Listing OL CRNA

About Circio Holding ASA

https://www.targovax.com/en/

Circio Holding ASA is a clinical-stage company developing novel medicines based on circular RNA (circRNA) and immunotherapy. The company's core focus is its proprietary circVec platform, a circular RNA expression system designed to enhance the efficacy and durability of gene and cell therapies. Circio's development pipeline is directed towards immuno-oncology, targeting difficult-to-treat solid tumors, and the application of its circRNA technology to address genetic diseases.

Recent filings

Filing Released Lang Actions
Circio Holding ASA: Ex. right to participate in potential subsequent offering today
Share Issue/Capital Change Classification · 87% confidence The document is a stock exchange announcement regarding the ex-right date for participation in a subsequent offering of up to 7,638,888 new shares, i.e., a rights issue/new share issue. This clearly falls under “Share Issue/Capital Change” rather than a general financing update.
2026-04-08 English
Circio Holding ASA: Key information relating to potential subsequent offering
Share Issue/Capital Change Classification · 85% confidence The document is a stock exchange announcement providing key details on a potential subsequent offering of new shares (a repair offering) including dates, subscription price, maximum shares, record date, and conditions. It is clearly a financing activity related to issuing new equity. This fits the definition of a Share Issue/Capital Change announcement (code SHA), rather than a full Annual Report or regulatory filing.
2026-04-08 English
Circio announces that it has completed a significantly oversubscribed financing of NOK 250 million
Share Issue/Capital Change Classification · 89% confidence The document is a press release announcing the completion of a directed share issue (private placement) raising NOK 250 million, details of the subscription price, share capital increase, settlement, and a planned subsequent offering. This is an announcement of a new share issue and related capital change, matching the “Share Issue/Capital Change” category.
2026-04-08 English
Circio Holding ASA Key events and financial highlights 2H 2025 and YTD 2026 - Attachment: Key Events And Financial Highlights 2H 2025 And YTD 2026.pdf
Interim / Quarterly Report Classification · 95% confidence The document provides a comprehensive summary of financial performance for the second half of 2025, including a profit and loss statement, balance sheet highlights, and a discussion on the going concern status. It contains substantive financial data for a period shorter than a full fiscal year (2H 2025), which aligns with the definition of an Interim/Quarterly Report (IR). H2 2025
2026-04-08 English
Circio Holding ASA Key events and financial highlights 2H 2025 and YTD 2026
Earnings Release Classification · 90% confidence The document is a preliminary and unaudited set of key financial highlights and events for 2H 2025 and YTD 2026, presented in bullet form with headline metrics (e.g., net cash, rights issue proceeds) rather than a full interim report. It functions as the company’s initial announcement of periodical financial results (high‐level summary). This matches the definition of an Earnings Release (ER). H2 2025
2026-04-08 English
Circio enters in vivo cell therapy collaboration with United Immunity
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing a research collaboration between Circio and United Immunity. It does not contain financial results, governance changes, funding details, or meeting materials. It falls under general corporate announcements that do not fit other specific categories. Therefore, it is classified as a Regulatory Filing (RNS).
2026-03-26 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.